Their belief system is a little different than most folks.
They have leading edge technology. You will see over time so continue to accumulate.
ABT 199, TGTX 1101 and 1102, CAL 101, Idealilisib, GA 101, IP-145, Obinituzumab, Arzerra, Ofatumumab, MOR 208, MOR 202, Genetically modified T Killer cells from Univ of Pennsylvania, Kanzius Cancer Treatment. Get a clue so many others are on the band wagon. Deep competition bring price competition. That is good for all those with CLL.
and will rocket from there if, when Duggan changes his pricing strategy. Otherwise we will break $90.00. There are far too many other drugs that can replace Ibrutinib as the drug of choice. Whoever prices the drug at the right price will when on volume orders. Be forewarned.Duggan can be so in the drivers seat but he chooses to be even more greedy. This drug was already developed and does not need to recoup his development costs. Good Grief. Pigs get slaughtered.
Louis J. Winthorpe is lead analyst spearing the leverage buyout. Billy J Valentine is representing the firm of Duke and Duke. GLTA
They are charging too damn much when the alternatives are cheaper and work just as good. GLTA
Jealously, revenge and untruth will wear on the mind and body and he will eventually pass away of an early death due to some disease that there is a drug for but he will refuse to take because he previously slammed the company. How sad.
This guy is a real piece of work. Everyone runs around like he is some god or something. Directors have every right to do what they have done. You invest in a company for the product and its results not some directors buy and sell plans on any given stock. good grief. Spread your risk and you will be ok. This is only a very small part of my overall plan. GLTA